Stay updated with breaking news from Sarepta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Sarepta Therapeutics soared 29% premarket on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy... | May 15, 2023
Monday May 15, 2023 Trading Desk: (312) 236-8907 TODAY’S GAME PLAN: from the trading desk, this is not research DATA/HEADLINES 8:30ET Empire Manufacturing, Fed's Goolsbee speaks; 9:15ET Fed's Kashkari speaks; 5:00ET Fed's Cook speaks Fed’s Bostic speaks (7:30am, 8:45am, 2pm, 3pm) TODAY’S HIGHLIGHTS: President Biden to meet Tuesday with House Leader McCarthy on the debt
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection.
In a proposed class action filed in Manhattan federal court, Joanne Noriega said she bought PediaSure Grow & Gain vanilla and strawberry drinks for her eight-year-old grandson, who was "short for his age," believing they would help him get taller. Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp's ArcherDX for infringing patents related to cancer detection.